These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. First steps to creating a platform for high throughput simulation of TTFields. Hershkovich HS; Bomzon Z; Wenger C; Urman N; Chaudhry A; Garcia-Carracedo D; Kirson ED; Weinberg U; Wassermann Y; Palti Y Annu Int Conf IEEE Eng Med Biol Soc; 2016 Aug; 2016():2357-2360. PubMed ID: 28268799 [TBL] [Abstract][Full Text] [Related]
6. Current status of the preclinical evaluation of alternating electric fields as a form of cancer therapy. Pohling C; Nguyen H; Chang E; Schubert KE; Nie Y; Bashkirov V; Yamamoto V; Zeng Y; Stupp R; Schulte RW; Patel CB Bioelectrochemistry; 2023 Feb; 149():108287. PubMed ID: 36306728 [TBL] [Abstract][Full Text] [Related]
7. The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma. Riley MM; San P; Lok E; Swanson KD; Wong ET J Vis Exp; 2019 Apr; (146):. PubMed ID: 31058901 [TBL] [Abstract][Full Text] [Related]
8. What is the Role of Tumor-treating Fields in Newly Diagnosed Glioblastoma? Ornelas AS; Porter AB; Sharma A; Knox MG; Marks LA; Wingerchuk DM; O'Carroll CB Neurologist; 2019 Mar; 24(2):71-73. PubMed ID: 30817495 [TBL] [Abstract][Full Text] [Related]
9. Tumor treating fields: a novel treatment modality and its use in brain tumors. Hottinger AF; Pacheco P; Stupp R Neuro Oncol; 2016 Oct; 18(10):1338-49. PubMed ID: 27664860 [TBL] [Abstract][Full Text] [Related]
10. Rationale and Background on Tumor-Treating Fields for Glioblastoma. Schwartz MA; Onuselogu L Clin J Oncol Nurs; 2016 Oct; 20(5 Suppl):S20-4. PubMed ID: 27668387 [TBL] [Abstract][Full Text] [Related]
11. Tumor treating fields: a new frontier in cancer therapy. Davies AM; Weinberg U; Palti Y Ann N Y Acad Sci; 2013 Jul; 1291():86-95. PubMed ID: 23659608 [TBL] [Abstract][Full Text] [Related]
12. AMPK-dependent autophagy upregulation serves as a survival mechanism in response to Tumor Treating Fields (TTFields). Shteingauz A; Porat Y; Voloshin T; Schneiderman RS; Munster M; Zeevi E; Kaynan N; Gotlib K; Giladi M; Kirson ED; Weinberg U; Kinzel A; Palti Y Cell Death Dis; 2018 Oct; 9(11):1074. PubMed ID: 30341282 [TBL] [Abstract][Full Text] [Related]
13. Tumor Treating Fields Technology: Alternating Electric Field Therapy for the Treatment of Solid Tumors. Benson L Semin Oncol Nurs; 2018 May; 34(2):137-150. PubMed ID: 29631935 [TBL] [Abstract][Full Text] [Related]
14. Functional Biological Activity of Sorafenib as a Tumor-Treating Field Sensitizer for Glioblastoma Therapy. Jo Y; Kim EH; Sai S; Kim JS; Cho JM; Kim H; Baek JH; Kim JY; Hwang SG; Yoon M Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30469352 [TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Treating Glioblastoma With Tumor-Treating Fields Therapy. Saria MG; Kesari S Clin J Oncol Nurs; 2016 Oct; 20(5 Suppl):S9-S13. PubMed ID: 27668388 [TBL] [Abstract][Full Text] [Related]
17. The electric field distribution in the brain during TTFields therapy and its dependence on tissue dielectric properties and anatomy: a computational study. Wenger C; Salvador R; Basser PJ; Miranda PC Phys Med Biol; 2015 Sep; 60(18):7339-57. PubMed ID: 26350296 [TBL] [Abstract][Full Text] [Related]
18. Determining the Optimal Inhibitory Frequency for Cancerous Cells Using Tumor Treating Fields (TTFields). Porat Y; Giladi M; Schneiderman RS; Blat R; Shteingauz A; Zeevi E; Munster M; Voloshin T; Kaynan N; Tal O; Kirson ED; Weinberg U; Palti Y J Vis Exp; 2017 May; (123):. PubMed ID: 28518093 [TBL] [Abstract][Full Text] [Related]